At close: September 26 at 4:00 PM EDT
After hours: September 26 at 4:20 PM EDT
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 10 | 10 | 9 | 10 |
| Avg. Estimate | -0.49 | -0.5 | -1.81 | -2.09 |
| Low Estimate | -0.52 | -0.53 | -1.87 | -2.3 |
| High Estimate | -0.43 | -0.44 | -1.71 | -1.95 |
| Year Ago EPS | -0.44 | -0.49 | -1.96 | -1.81 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 6 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.46 | -0.49 | -0.44 | -0.41 |
| EPS Actual | -0.44 | -0.49 | -0.37 | -0.45 |
| Difference | 0.02 | 0 | 0.07 | -0.04 |
| Surprise % | 4.30% | 0.00% | 15.90% | -9.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.49 | -0.5 | -1.81 | -2.09 |
| 7 Days Ago | -0.49 | -0.5 | -1.81 | -2.07 |
| 30 Days Ago | -0.48 | -0.5 | -1.81 | -2.09 |
| 60 Days Ago | -0.43 | -0.46 | -1.72 | -1.93 |
| 90 Days Ago | -0.43 | -0.46 | -1.72 | -1.93 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | -- | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | ORIC | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -11.40% | -- | -- | 5.70% |
| Next Qtr. | -2.00% | -- | -- | 9.70% |
| Current Year | 7.70% | -- | -- | 3.40% |
| Next Year | -15.50% | -- | -- | 12.60% |
| Next 5 Years (per annum) | -- | -- | -- | 11.90% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight | 9/23/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/18/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 9/10/2024 |
| Reiterates | Cantor Fitzgerald: Overweight | 9/9/2024 |
| Initiated | Stifel: Buy | 9/6/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/14/2024 |
Related Tickers
ERAS Erasca, Inc.
2.7100
-1.09%
OLMA Olema Pharmaceuticals, Inc.
12.22
-1.45%
ITOS iTeos Therapeutics, Inc.
10.17
+0.74%
SLRN Acelyrin, Inc.
4.8800
+2.09%
RLAY Relay Therapeutics, Inc.
7.40
+4.82%
KROS Keros Therapeutics, Inc.
56.88
+0.76%
CABA Cabaletta Bio, Inc.
3.9900
+1.01%
NRIX Nurix Therapeutics, Inc.
23.21
-1.36%
RVMD Revolution Medicines, Inc.
43.86
-2.23%
FDMT 4D Molecular Therapeutics, Inc.
10.96
-2.84%